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Abstract
Background: A rapid worldwide increase in the number of human infections caused by the extremely antibiotic
resistant bacterium Stenotrophomonas maltophilia is prompting alarm. One potential treatment solution to the
current antibiotic resistance dilemma is “phage therapy”, the clinical application of bacteriophages to selectively kill
bacteria.
Results: Towards that end, phages DLP1 and DLP2 (vB_SmaS-DLP_1 and vB_SmaS-DLP_2, respectively) were
isolated against S. maltophilia strain D1585. Host range analysis for each phage was conducted using 27 clinical S.
maltophilia isolates and 11 Pseudomonas aeruginosa strains. Both phages exhibit unusually broad host ranges
capable of infecting bacteria across taxonomic orders. Transmission electron microscopy of the phage DLP1 and
DLP2 morphology reveals that they belong to the Siphoviridae family of bacteriophages. Restriction fragment length
polymorphism analysis and complete genome sequencing and analysis indicates that phages DLP1 and DLP2 are
closely related but different phages, sharing 96.7 % identity over 97.2 % of their genomes. These two phages are
also related to P. aeruginosa phages vB_Pae-Kakheti_25 (PA25), PA73, and vB_PaeS_SCH_Ab26 (Ab26) and more
distantly related to Burkholderia cepacia complex phage KL1, which together make up a taxonomic sub-family.
Phages DLP1 and DLP2 exhibited significant differences in host ranges and growth kinetics.
Conclusions: The isolation and characterization of phages able to infect two completely different species of
bacteria is an exciting discovery, as phages typically can only infect related bacterial species, and rarely infect
bacteria across taxonomic families, let alone across taxonomic orders.
Keywords: Stenotrophomonas maltophilia, Bacteriophage, Phage, DNA, Genomics, Phage genome, Delayed lysis,
Broad-host-range
Background
The rise in antibiotic resistance amongst bacterial patho-
gens around the world is causing alarm, with the possibil-
ity of a “post-antibiotic era” in the 21st century [1]. One
broadly antibiotic-resistant bacterium that is increasing in
prevalence in nosocomial and community-acquired infec-
tions is Stenotrophomonas maltophilia. Some of the infec-
tions associated with S. maltophilia include pneumonia,
bacteremia, meningitis, endocarditis, catheter-related
bacteremia/septicemia and acute exacerbations in patients
with cystic fibrosis and chronic obstructive pulmonary dis-
ease [2, 3]. Preventing infections caused by this bacterium
is difficult, as S. maltophilia is ubiquitous in the environ-
ment and can be easily spread in nosocomial settings by
health care providers and cough-generated aerosols [2, 4].
Treatment of S. maltophilia infections is problematic due
to its innate resistance to a broad array of antibiotics such
as trimethoprim/sulfamethoxazole, β-lactams, macrolides,
cephalosporins, fluoroquinolones, aminoglycosides, carba-
penems, chloramphenicol, tetracyclines and polymyxin.
New treatment strategies are thus required in order to
successfully combat this extremely drug-resistant
bacterium.
One promising treatment strategy is the clinical appli-
cation of bacteriophages, also known as phage therapy,
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to selectively kill infecting bacteria [5–10]. Phage therapy
has been used for nearly a century in some Eastern
European countries, but was largely abandoned in the
West during the 1940s due to the advent of broad-
spectrum antibiotics. However, with the rise in antibiotic
resistance threatening the traditionally effective treat-
ment of bacterial infections, rigorous research into the
efficacious use of phage therapy has been renewed. Re-
cent studies utilizing phage therapy in animal models
[11–17] and human clinical trials [18–20] have shown
that phages can be a successful treatment option. In
order to obtain FDA approval for the clinical use of
phages, proof is required to show that phage genomes
do not encode toxins or other undesirable genes that
could potentially enhance bacterial virulence [21].
Therefore, all S. maltophilia-specific phages that are to
be considered for use in a phage therapy strategy must
be fully characterized through complete genome sequen-
cing and analysis to ensure they are safe for use in
human clinical trials.
Recent research has led to the isolation and
characterization of several different S. maltophilia
phages, including a jumbo phage phiSMA5 (with a
genome of approximately 250 kb in length, [22]), a fila-
mentous phage phiSMA9 with a genome size of 6.9 kb
encoding only seven genes, but one of these being a
zot toxin [23], a virulent phage Smp14 that exhibits
homology to phage T4 [24], a lytic phage IME13 with
an unusually large burst size [25], a T7-like phage
IME15 specific to S. maltophilia [26], a P2-like phage
Smp131 whose genome exhibits sequence homology to
prophages in Xanthomonas species [27], and three
other novel, small filamentous phages phiSMA 6,
phiSMA7 and phiSHP1 [28, 29]. Twenty-two phages
specific for different Stenotrophomonas species, includ-
ing the well-characterized temperate phage S1, have
also recently been isolated [30]. Additional pertinent
research has shown that non-interactive Lactococcus
phages can easily penetrate the biofilms produced by S.
maltophilia [31, 32]. Here we describe the isolation
and characterization of two novel S. maltophilia phages
DLP1 and DLP2. These phages are related to three previ-
ously characterized Pseudomonas aeruginosa phages and
have the unusual characteristic of cross-taxonomic order
infectivity, the ability to use strains of both S. maltophilia
and P. aeruginosa as hosts for phage propagation.
Results and discussion
Isolation, host range and morphology
Using S. maltophilia strain D1585, phages DLP1 and
DLP2 were isolated from Red Deer River sediment and
soil planted with blue flax (Linum lewisii), respectively.
In contrast to the characterized S. maltophilia phages
isolated from clinical settings, sewage samples and
lysogenic bacteria [22–30], DLP1 and DLP2 are the first
phages to be isolated from sediment and soil.
Phage DLP1 exhibits a unique plaque development
that was previously identified in phages KL1 and AH2
that target bacteria of the Burkholderia cepacia complex
[33]. As with KL1 and AH2, stocks of DLP1 can be con-
centrated (up to 1010 plaque forming units [PFU]/ml),
but use of such high titre stocks results in plates with no
plaques. Instead, when lower titres (107 PFU/ml or less)
are used, and the plates are incubated at 30 °C for at
least 24 h, DLP1 plaque development occurs (Fig. 1). In-
dividual plaques for DLP1 are turbid with no distinct
boarders and a diameter of 0.4-1 mm, averaging 0.7 mm.
This contrasts the plaque development of phage DLP2,
which produces clearing at high titres and clearly defined
plaques at lower titres following 16 h incubation at 30 °C
(Fig. 1). Plaque sizes for DLP2 are clear with distinct
boarders and a diameter 0.2-0.8 mm, averaging 0.4 mm.
DLP1 and DLP2 are classified in the order Caudovirales
and the family Siphoviridae due to their morphological
characteristics observed using electron microscopy. The
DLP1 phage has a long, non-contractile tail of approxi-
mately 175 nm in length and a capsid size of approxi-
mately 70 nm in diameter (Fig. 2a). Phage DLP2 is larger,
with a non-contractile tail of approximately 205 nm and a
capsid size of approximately 70 nm in diameter (Fig. 2b).
Both DLP1 and DLP2 have a moderate host range
within the S. maltophilia strains tested, with the ability to
infect eight and nine out of 27 strains, respectively
(Table 1). Both phages also have a unique ability to infect
across bacterial taxonomic orders, with each phage cap-
able of infecting two separate P. aeruginosa strains each
(Table 2, Additional file: 1Table S1). This is an interesting
finding, as bacteriophages are typically thought to be rela-
tively species specific. However, there are examples of bac-
teriophages that have been shown to lyse bacteria of
different genera. For example, some phages originally dis-
covered to infect one genus of Cyanobacteria, have also
been shown to be able to lyse other Cyanobacteria genera
[34–36]. Confirmation of successful DLP1 and DLP2 in-
fection and lysis of P. aeruginosa strains was confirmed
with the use of PCR (Fig. 3).
Genome characterization
Genomic analysis of phages DLP1 and DLP2 reveals they
are closely related phages. Initially, a comparison of re-
striction fragment length polymorphisms (RFLPs) of
DLP1 and DLP2 EcoRI-digested genomic DNA shows
similar banding patterns with slight band differences be-
tween 0.85-1, 2-3 and 5 kbp (Fig. 4). DLP1 and DLP2
similarity was confirmed by the results of the whole gen-
ome sequencing using the Illumina platform (discussed
below). A genome map for DLP1 and DLP2 (Fig. 5)
shows the modular similarity of the two phages, as well
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as their genetic similarity with respect to their genes and
genome sizes. However, complete genome sequencing
also demonstrates the crudeness of RFLP analysis. The
DLP1 genome contains 31 EcoRI sites, whereas the
DLP2 genome possesses 32 EcoRI sites. Phage DLP1
possesses five DNA insertions of 29 bp in EcoRI frag-
ment 6869-9910, 40 bp in fragment 9910-10,628, 50 bp
in fragment 12,987-13,729, 129 bp in fragment 24,500-
27,657 and 118 bp in fragment 34,709-39,879. Phage
DLP2 possesses three DNA insertions of 40 bp in EcoRI
fragment 10,559-11,971, 87 bp in fragment 14,003-
14,999, and 5 bp in fragment 29,984-31,617. In addition,
phage DLP2 has an extra EcoRI site at base pair 3345
due to a point mutation. Phages DLP1 and DLP2 were
found to be 96.7 % identical over 97.2 % of their genomes.
However, this comparison still denotes considerable
Fig. 1 Development and morphology of DLP1 and DLP2 plaques. Phages were plated in half-strength Luria-Bertani (½ LB) agar overlays with
16 h liquid culture of Stenotrophomonas maltophilia D1585. Plates were incubated at 30 °C and photographed at 16, 24 and 48 h. Turbid DLP1
plaques were difficult to visualize until after 24 h of growth, whereas clear, well-defined DLP2 plaques were observed after 16 h
Fig. 2 DLP1 (a) and DLP2 (b) phage morphology. Phages were stained with 4 % uranyl acetate and visualized at 180,000-fold magnification by
transmission electron microscopy. Scale bars represent 50 nm. Both Siphoviridae family phages were of similar size, although the tail of DLP1
(175 nm) was shorter than that of DLP2 (205 nm)
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variation between the two phage genomic sequences. A
BLASTN comparison indicates that the two genomes
share 40,317 identical base pairs out of 41,687 aligned
base pairs (1200 base pairs unaligned), with 166 gaps. The
similarity of DLP1 and DLP2 to each other, and to their
closest relative Pseudomonas phage vB_Pae-Kakheti25
(informally PA25), is illustrated in Fig. 6, a Circos plot of a
NUCmer comparison of the three phages.
The DLP1 genome is 42,887 base pairs (bp) in length,
with a GC content of 53.7 %. DLP1 is predicted to en-
code 57 proteins with the most common start codon be-
ing ATG, although a TTG start codon is used for gp19,
gp37 and gp41 (Table 3, Fig. 5). Besides phage DLP2,
phage DLP1 is most closely related to the siphovirus
Pseudomonas phage vB_Pae-Kakheti25 (PA25) (Fig. 6)
[37]. DLP1 and PA25 phages are similar with respect to
genome length (42,844 bp for PA25 and 42,887 bp for
DLP1), GC content (53.7 % for PA25 and DLP1) and
predicted number of proteins (58 for PA25 and 57 for
DLP1) [37]. BLASTN comparison of DLP1 and PA25
shows a 98 % identity over 94 % of the genome. The
genome of DLP1 also shows high similarity to phages
PA73 (98 % identity over 92 % of the genome) [38] and
vB_PaeS_SCH_Ab26 (Ab26) (96 % identity over 92 % of
the genome) [37]. Again, this represents a significant
amount of genetic variation, with 145 gaps required to
complete the genomic alignment with PA25, 144 gaps
required to align PA73, and 220 gaps required to align
Ab26, suggesting that although these phages belong to
the same family, they are not merely variants of one
another. The predicted proteins of DLP1 are similar to
those found in phages PA25, PA73 and Ab26; though
DLP1 proteins gp32, gp45 and gp48 are unique in that
they are not similar to any proteins found in PA25,
PA73 and Ab26 (Table 3). The DLP1 protein gp32 is re-
lated to gp055 of the Erwinia phage vB_EamP-S6. The
gp45 protein is related to the hypothetical protein
X805_23910 of Sphaerotilus natans subsp. natans DSM
Table 1 Host range analysis of DLP1 and DLP2 against
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6575, which is a filamentous bacterium known to con-
tribute to the stability of Pseudomonas sp. colonies at
low concentrations [39]. The Vsr endonuclease encoded
by gp48 is most homologous to a gene found in the Bur-
kholderia phage KL1 [33].
The DLP2 genome is 42,593 bp in length, with a GC
content of 53.7 %. DLP2 is predicted to encode 58 pro-
teins with the most common start codon being ATG, al-
though a TTG start codon is used for gp19 and gp37,
and a GTG start codon is used for gp43 and gp55
(Table 4, Fig. 5). Phage DLP2 is also related to Pseudo-
monas phage PA25 (Fig. 6). These two phages are similar
with respect to genome length (42,844 bp for PA25 and
42,593 for DLP2), GC content (53.7 % for PA25 and
DLP2) and predicted number of proteins (58 for PA25
and DLP2) [40]. BLASTN comparison of the DLP2 and
PA25 genomes shows a 97 % identity over 95 % of the
genome. The BLASTN results also reveals DLP2 to be
similar to Pseudomonas phages PA73 (98 % identity over
93 % of genome) [38] and Ab26 (97 % identity over 90 %
of the genome) [37]. Phage DLP2 gene content differs
from phages PA25, PA73 and Ab26 in predicted pro-
teins gp39 and gp45 (Table 4). DLP2 protein gp39 is
most closely related to the uncharacterized protein
MAM_066 of the Serratia phage ΦMAM1. Similar to
DLP1, the DLP2 gp45 protein is related to the hypo-
thetical protein X805_23910 of Sphaerotilus natans
subsp. natans DSM 6575.
Analysis of modules
The proteins identified in DLP1 and DLP2 can be classi-
fied into three general categories: lysis, virion morpho-
genesis (including DNA packing and capsid/tail
morphogenesis) and DNA replication/repair. The ORFs
of DLP1 and DLP2 are syntenic, and the predicted pro-
teins are similar with only a few variations from each
other (Tables 3 and 4), yet these two phages exhibit two
completely different plaque development characteristics
(Fig. 1). It is also of interest to note that no genes encod-
ing known or putative virulence factors were discovered
in the genomes of phages DLP1 and DLP2, or any other
related phages in this family.
Lysis
Genes putatively encoding the lysis proteins holin, lysin,
Rz, Rz1 and a hypothetical protein have been identified
in DLP1. A BLASTP search of predicted protein gp1
shows that it is similar to a phage protein family found
in lysis cassettes that was identified in phage PA25. A
BLASTP search also showed gp2 to be a putative holin
protein similar to those identified in PA25 and PA73.
Analysis of this gp2 protein with TMHMM revealed it
has two transmembrane domains; thus, gp2 is a pre-
dicted to be a class II holin [40]. Gene gp3 is nearly
identical to the endolysin of PA25. Gp4 and gp5 proteins
are similar to the Rz protein of Ab26 and Rz1 of PA25
respectively. The Rz protein is a class II inner membrane
Fig. 3 PCR confirmation of P. aeruginosa infections by DLP1 and DLP2. Lanes 1 and 9: 1 Kb Plus DNA ladder (Invitrogen), lane 2: DLP1 phage
DNA, lane 3: DLP1 negative control, lane 4: DLP1 phage lysate, lane 5: DLP2 phage DNA, lane 6: DLP1 phage lysate from PA01 infection, lane 7:
DLP1 phage lysate from ENV009 infection, lane 8: blank, lane 10: DLP2 phage DNA, lane 11: DLP2 negative control, lane 12: DLP2 phage lysate,
lane 13: DLP1 phage lysate, lane 14: DLP2 phage lysate from HER004 infection, lane 15: DLP2 phage lysate from 14,715 infection. The size of the
markers (in Kbp) is shown on the left
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protein with an N-terminal domain and Rz1 is a proline-
rich outer membrane lipoprotein [41]. The Rz/Rz1 pro-
teins contribute to lysis by fusing to the inner and outer
membranes following holin and endolysin activity to fa-
cilitate phage release [42]. The gp4 protein is predicted
to contain a single N-terminal transmembrane domain,
a characteristic of Rz proteins [40, 43]. LipoP analysis of
gp5 shows a signal peptidase II cleavage site between
amino acids 20 and 21, resulting in a 73 amino acid pro-
tein with 7 proline residues (9.6 % proline) [44].
The lysis predicted proteins identified in DLP2 are
similar to those also identified in phage DLP1. However,
there are also some differences. The gp3 of DLP2 is
most closely related to ORF003 of PA73 and also the
endolysin protein in PA25. Like DLP1, gp4 of DLP2 is
similar to the Rz protein of phage Ab26. Although DLP2
gp5 required manual annotation, BLASTP analysis
showed it is most closely related to Rz1 of Ab26, rather
than phage PA25. However, LipoP analysis revealed the
identical signal peptidase II cleavage site as for phage
DLP1 gp5. Analysis of the lysis module for DLP1 and
DLP2 did not reveal why phage DLP1 exhibits delayed
plaque development when compared to phage DLP2.
One hypothesis is that gp32 of DLP1, encoding a hypo-
thetical protein not found in DLP2 (most closely related
to gp055 of Erwinia phage vB_EamP-S6), contributes to
the delayed plaque development of DLP1. However, until
a definitive function for the DLP1 gp32-encoded protein
can be established, this hypothesis remains unproven.
Virion morphogenesis
As discussed above, DLP1 is closely related to phage
DLP2, and phages PA25, Ab26 and PA73, whose pro-
teins are generally uncharacterized. BLASTP analysis of
the 20 genes involved in virion morphogenesis in DLP1
identified 13 genes with putative functions: two involved
in DNA packaging, four involved in capsid morphogen-
esis and seven involved in tail morphogenesis. The DNA
packaging proteins gp6 (small terminase subunit) and
gp7 (large terminase subunit) are similar to the small
terminase subunit of PA25 and large terminase subunit
of Ab26 respectively. Protein gp8 shares a 98 % identity
to the portal protein of Ab26. Although gp9 shares
100 % identity to uncharacterized ORF008 of PA73, it
Fig. 4 Restriction fragment length polymorphism of DLP1 and DLP2
genomic DNA. 1 μg of phage genomic DNA was digested 5 min
with EcoRI and separated on a 1 % agarose gel. L: 1 Kb Plus DNA
Ladder (Invitrogen). Several differences in banding pattern between
the genomic DNAs isolated from the two phages is apparent
Fig. 5 Genome maps of DLP1 and DLP2. The scale (in kbp) is shown above the DLP1 and DLP2 genomic maps. The assigned function of the predicted
proteins encoded by each open reading frame is as follows: grey - unknown function; purple - lysis; green - virion morphogenesis; blue - DNA
replication/repair. Numbers within the larger ORFs relate to gene product number
Peters et al. BMC Genomics  (2015) 16:664 Page 6 of 15
has been assigned a putative function due to its high
similarity to the F-like head morphogenesis protein of
Ab26 (Table 3). Gp10 shares 100 % identity to the scaf-
fold protein of PA25. The gp11 is most similar to
ORF010 of PA73, but its high similarity to the major
capsid protein of Ab26 has allowed a putative function
to be assigned to this protein (Table 3). The seven pro-
teins involved in tail morphogenesis are gp15 (head-tail
joining protein), gp16 (minor tail protein), gp17 (major
tail protein), gp18 (tail chaperonin), gp19 (tail chaper-
onin), gp21 (tape measure protein) and gp26 (central tail
hub). Both gp15, closely related to the virion protein of
Ab26, and gp16, closely related to ORF015 of PA73, have
been assigned putative functions due to their similarities
to the head-tail joining protein and minor tail protein of
Burkholderia phage KL1 respectively (Table 3) [33]. Pro-
tein gp17 shares a 99 % identity to the major tail protein
of PA25. Gp17 is 100 % identical to ORF017 of PA73,
but has been assigned the putative function of tail
chaperonin due to its similarity to Ab26 tail chaperonin.
Like gp17, gp18 is predicted to be a tail chaperonin pro-
tein, and has 100 % identity to the PA25 tail chaperonin
protein. Both gp21 and gp26 are closely related to the
tape measure protein and central tail hub of PA25, re-
spectively. Analysis of DLP2 with BLASTP revealed the
virion morphogenesis proteins are nearly identical to
those of DLP1, with only minor differences (Table 4).
DNA replication and repair
DLP1 and DLP2 have seven and eight identified proteins,
respectively, identified to be involved in DNA replication
and repair at the same gene position: DNA polymerase
(gp27), replicative clamp (gp28), RecB exonuclease (gp31 -
DLP2 only), RecA (gp34), MazG (gp36), replicative pri-
mase/helicase (gp39), Vsr endonuclease (gp48) and dCMP
deaminase (gp54 in DLP1, gp55 in DLP2) (Tables 3 and 4;
Fig. 5). Three and two additional proteins were assigned
putative functions following bioinformatics analysis, in
Fig. 6 Circos plot of genomes from phages DLP1, DLP2 and vB_Pae-Kakheti25 (PA25) NUCmer comparisons. Green ribbon indicates regions of
similarity between the three genomes at the nucleotide level. The scale (in kbp) is shown on the periphery of the plot for each phage. NUCmer
parameters: breaklen = 200, maxgap = 90, mincluster = 65, minmatch = 20
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Table 3 Bacteriophage DLP1 genome annotation




1 1 255 Hypothetical protein + 84 ORF001 100 PA73 YP_001293408.1
2 252 518 Holin + 88 Holin 99 PA25 YP_006299866.1
3 511 1,056 Endolysin + 181 Endolysin 98 PA25 YP_006299867.1
4 1068 1373 Rz + 101 Rz 99 Ab26 YP_009044338.1
5 1288 1569 Rz1 + 93 Rz1 100 PA25 YP_006299869.1
6 1627 2115 Small terminase + 162 Small terminase 99 PA25 YP_006299870.1
7 2096 3691 Large terminase + 531 Large terminase 100 Ab26 YP_001293413.1
8 3705 5210 Portal protein + 501 Portal protein 98 Ab26 YP_009044342.1
9 5222 6316 F-like head morphogenesis
protein
+ 364 ORF008 100 PA73 YP_001293415.1
10 6353 7072 Scaffold protein + 239 Scaffold protein 100 PA25 YP_006299874.1
11 7075 8052 Major capsid protein + 325 ORF010 99 PA73 YP_001293417.1
12 8122 8526 Hypothetical protein + 134 ORF011 100 PA73 YP_001293418.1
13 8592 8993 Hypothetical protein + 133 ORF12 71 Ab26 YP_009044347.1
14 9005 9523 Hypothetical protein + 172 Hypothetical protein 92 Ab26 YP_009044348.1
15 9527 9907 Head-tail joining protein + 126 Hypothetical protein 98 PA25 YP_006299879.1
16 9904 10,359 Minor tail protein + 151 ORF015 97 PA73 YP_001293422.1
17 10,372 11,907 Major tail tube protein + 511 Major tail tube protein 99 PA25 YP_006299881.1
18 11,971 12,399 Tail chaperonin + 142 ORF017 100 PA73 YP_001293424.1
19 12,408 12,764 Tail chaperonin + 118 Tail chaperonin 100 PA25 YP_006299882.1
20 12,733 13,167 Hypothetical protein + 144 ORF019 100 PA73 YP_001293426.1
21 13,173 16,708 Tape measure protein + 1175 Tape measure protein 96 PA25 YP_006299885.1
22 16,701 17,663 Hypothetical protein + 320 Hypothetical protein 87 PA25 YP_006299886.1
23 17,663 18,628 Hypothetical protein + 321 Hypothetical protein 64 PA25 YP_006299887.1
24 18,634 20,346 Hypothetical protein + 570 Hypothetical protein 96 PA25 YP_006299888.1
25 20,346 21,170 Hypothetical protein + 274 Hypothetical protein 99 PA25 YP_006299889.1
26 21,174 23,615 Central tail hub + 813 Central Tail Hub 99 PA25 YP_006299890.1
27 23,616 25,667 DNA polymerase - 683 DNA polymerase 99 PA25 YP_006299891.1
28 25,679 26,821 Replicative clamp - 380 Replicative clamp 99 PA25 YP_006299892.1
29 26,805 27,161 Hypothetical protein - 118 ORF028 97 PA73 YP_001293435.1
30 27,166 28,821 DEAD box helicase - 551 ORF029 100 PA73 YP_001293436.1
31 28,814 29,911 RecB exonuclease - 365 ORF030 100 PA73 YP_001293437.1
32 29,817 30,344 Hypothetical protein - 175 gp055 41 EamP-S6a YP_007005791.1
33 30,423 31,169 Hypothetical protein - 248 Member of the DUF669
phage protein family
99 PA25 YP_006299897.1
34 31,228 31,944 RecA - 238 RecA 99 Ab26 YP_009044366.1
35 31,999 32,439 Hypothetical protein - 146 ORF033 99 PA73 YP_001293440.1
36 32,516 33,073 MazG - 185 MazG 89 PA25 YP_006299900.1
37 33,193 33,399 Transcriptional regulator + 68 ORF035 100 PA73 YP_001293442.1
38 33,389 35,710 Replicative primase/helicase + 773 Replicative primase/helicase 99 PA25 YP_006299902.1
39 35,862 36,062 Hypothetical protein + 66 Hypothetical protein 99 Ab26 YP_009044372.1
40 36,107 36,256 Hypothetical protein + 49 KAK25_00040 96 PA25 YP_006299904.1
41 37,055 37,234 Hypothetical protein + 59 Hypothetical protein ORF0038 92 PA73 YP_001293445.1
42 37,231 37,527 Hypothetical protein + 98 ORF0039 98 PA73 YP_001293446.1
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DLP1 and DLP2, respectively, based on their high similar-
ities to known proteins: DEAD box helicase (gp30), RecB
exonuclease (gp31 - DLP1 only) and a transcriptional
regulator (gp37) (Tables 3 and 4; Fig. 5).
BLASTP analysis for DLP1 and DLP2 gp27 shows it is
99 % identical to a putative DNA polymerase in PA25.
The replicative clamp of PA25 shares a 99 % identity to
gp28 of DLP1 and 95 % identity to gp28 of DLP2. In
DLP1, gp31 is 100 % identical to ORF030 in PA73,
though its putative function was assigned due to its
95 % identity to the RecB exonuclease of Ab26. Gp31 in
DLP2 has 99 % identity to the RecB exonuclease of
Ab26. HHpred analysis of the gp31 protein for DLP1
and DLP2 revealed the proteins are similar to the exo-
nuclease of the λ Red recombination complex (DLP1:
99 %, E-value of 3.8e−17; DLP2: 99 %, E-value 5.6e−17)
[45]. The RecA protein of Ab26 shares 99 % and 100 %
identity to the gp34 proteins of DLP1 and DLP2, re-
spectively. The protein gp37 of DLP1 (100 % identity to
ORF035 of PA73) and DLP2 (99 % identity to hypothet-
ical protein in Ab26) have been assigned the putative
function of transcriptional regulator due to their similar-
ity to the transcriptional regulator of the Burkholderia
phage KL1 [33]. The protein gp38 for both DLP1 and
DLP2 shares 99 % identity to the replicative primase/
helicase found in PA25. Both DLP1 and DLP2 contain a
Vsr endonuclease (gp48), although gp48 of DLP1 is most
similar to KL1 Vsr endonuclease, whereas gp48 of DLP2
is most similar to the Vsr endonuclease encoded by
Ab26 (Tables 3 and 4). The dCMP deaminase (gp54 of
DLP1 and gp55 in DLP2) of both phages is most closely
related to the dCMP deaminase of PA25 (98 and 97 %
identity, respectively). Protein gp30 of DLP1 and DLP2
is 100 % identical to ORF029 of PA73, but a putative
function has been assigned in both phages, as gp30 is
99 % identical to the DEAD box helicase protein of
Ab26 for both phages. DEAD box helicases are vital in
RNA metabolism, as they function to fold RNA mole-
cules into their correct secondary structures and realign
RNA-protein interactions with the use of ATP [46].
A predicted protein of interest in DLP1 and DLP2 is
MazG, which is encoded by gp36 in DLP1 (89 % identity
to MazG of PA25), and gp36 in DLP2 (98 % identity to
MazG of Ab26). During times of stress in bacteria, the
unusual nucleotides pppGpp and ppGpp begin to accu-
mulate, synthesized by the proteins SpoT and RelA re-
spectively [47]. Amino acid starvation activates RelA to
synthesize ppGpp, whereas other bacterial stressors such
as carbon or nitrogen starvation triggers SpoT to
synthesize pppGpp [47, 48]. The pppGpp nucleotide can
be converted into ppGpp through the enzyme GppA
phosphatase [47]. Both of these unusual nucleotides are
involved in the global response to stressful conditions
within the bacteria, though ppGpp is a more potent
regulatory nucleotide for growth inhibition [47, 49].
MazG fits into this regulatory pathway by depleting the
accumulated ppGpp, thus reducing growth inhibition
[50]. The action of phage-encoded MazG has been of
interest to researchers, as many marine phages have
been found to encode MazG homologs [51]. It has been
speculated that phage-encoded MazG operates to reduce
the ppGpp pool within stationary-phase infected cells
[52], thus enhancing propagation of phage progeny in
bacterial cells growing in nutrient limiting conditions.
Table 3 Bacteriophage DLP1 genome annotation (Continued)
43 37,524 37,703 Hypothetical protein + 59 Hypothetical protein 90 Ab26 YP_009044375.1
44 37,678 37,920 Hypothetical protein + 80 Hypothetical protein 96 Ab26 YP_009044376.1
45 38,003 38,224 Hypothetical protein + 73 X805_23910 56 DSM 6575b KDB52021.1
46 38,271 38,645 Hypothetical protein + 124 KAK25_00046 99 PA25 YP_006299910.1
47 38,706 38,927 Hypothetical protein + 73 KAK25_00047 97 PA25 YP_006299911.1
48 38,924 39,415 Vsr endonuclease + 163 Vsr endonuclease 78 KL1c YP_006560795.1
49 39,403 39,618 Hypothetical protein + 71 Hypothetical protein 99 Ab26 YP_009044380.1
50 39,615 39,794 Hypothetical protein + 59 KAK25_00050 95 PA25 YP_006299914.1
51 39,855 40,154 Hypothetical protein + 99 ORF0045 81 PA73 YP_001293452.1
52 40,171 40,461 Hypothetical protein + 96 ORF0046 99 PA73 YP_001293453.1
53 40,454 40,687 Hypothetical protein + 77 KAK25_00053 100 PA25 YP_006299917.1
54 40,983 41,450 dCMP deaminase + 155 dCMP deaminase 98 PA25 YP_006299919.1
55 41,456 41,839 Hypothetical protein + 127 ORF0050 100 PA73 YP_001293457.1
56 41,874 42,083 Hypothetical protein + 69 ORF0051 96 PA73 YP_001293458.1
57 42,167 42,739 Hypothetical protein + 190 ORF0052 99 PA73 YP_001293459.1
aErwinia phage vB_EamP-S6
bSphaerotilus natans subsp. natans DSM 6575
cKL1 is Burkholderia phage KL1
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Table 4 Bacteriophage DLP2 genome annotation




1 1 255 Hypothetical protein + 84 Phage protein found in
lysis cassettes
96 PA25 YP_006299865.1
2 252 518 Holin + 88 Holin 95 PA25 YP_006299866.1
3 511 1056 Endolysin + 181 ORF003 100 PA73 YP_001293410.1
4 1068 1373 Rz + 101 Rz 100 Ab26 YP_009044338.1
5 1288 1569 Rz1 + 93 Rz1 100 Ab26 YP_009044339.1
6 1627 2115 Small terminase + 162 Small terminase 100 PA25 YP_006299870.1
7 2096 3691 Large terminase + 531 Large terminase 99 Ab26 YP_009044341.1
8 3705 5210 Portal protein + 501 Portal protein 99 Ab26 YP_009044342.1
9 5222 6316 F-like head
morphogenesis protein
+ 364 F-like head morphogenesis
protein
99 Ab26 YP_009044343.1
10 6353 7072 Scaffold protein + 239 Scaffold protein 98 PA25 YP_006299874.1
11 7075 8052 Major capsid protein + 325 ORF010 99 PA73 YP_001293417.1
12 8122 8526 Hypothetical protein + 134 ORF011 99 PA73 YP_001293418.1
13 8592 8963 Hypothetical protein + 123 ORF012 98 PA73 YP_001293419.1
14 8976 9494 Hypothetical protein + 172 Virion protein 100 PA25 YP_006299878.1
15 9498 9878 Head-tail joining protein + 126 Virion protein 98 Ab26 YP_009044349.1
16 9875 10,330 Minor tail protein + 151 ORF015 99 PA73 YP_001293422.1
17 10,343 11,878 Major tail tube protein + 511 Major tail tube protein 99 PA25 YP_006299881.1
18 11,942 12,370 Tail chaperonin + 142 Tail chaperonin 99 Ab26 YP_009044352.1
19 12,379 12,735 Tail chaperonin + 114 Tail chaperonin 99 Ab26 YP_009044353.1
20 12,704 13,138 Hypothetical protein + 144 ORF019 100 PA73 YP_001293426.1
21 13,144 16,711 Tape measure protein + 1187 Tape measure protein 99 PA25 YP_006299885.1
22 16,709 17,671 Hypothetical protein + 320 Virion protein 88 PA25 YP_006299886.1
23 17,671 18,636 Hypothetical protein + 321 Virion protein 64 PA25 YP_006299887.1
24 18,642 20,354 Hypothetical protein + 570 Virion protein 96 PA25 YP_006299888.1
25 20,354 21,178 Hypothetical protein + 274 Virion protein 99 PA25 YP_006299889.1
26 21,182 23,623 Central tail hub + 813 Central tail hub 99 PA25 YP_006299890.1
27 23,624 25,675 DNA polymerase - 683 DNA polymerase 99 PA25 YP_006299891.1
28 25,687 26,829 Replicative clamp - 380 Replicative clamp 97 PA25 YP_006299892.1
29 26,813 27,040 Hypothetical Protein - 76 KAK25_00029 100 PA25 YP_006299893.1
30 27,045 28,700 DEAD box helicase - 551 DEAD box helicase 99 Ab26 YP_009044363.1
31 28,693 29,790 RecB exonuclease - 365 RecB exonuclease 99 Ab26 YP_009044364.1
32 29,959 30,120 Hypothetical protein - 53 KAK25_00032 100 PA25 YP_006299896.1
33 30,302 31,054 Hypothetical protein - 251 Member of DUF669
phage protein family
99 PA25 YP_006299897.1
34 31,113 31,829 Rec A - 238 RecA 100 Ab26 YP_009044366.1
35 31,884 32,324 Hypothetical protein - 146 Hypothetical protein 99 Ab26 YP_009044367.1
36 32,401 32,958 MazG - 185 MazG 98 Ab26 YP_009044368.1
37 33,078 33,284 Transcriptional regulator + 68 Hypothetical protein 99 Ab26 YP_009044369.1
38 33,274 35,595 Replicative Primase/Helicase + 773 Replicative primase/helicase 99 PA25 YP_006299902.1
39 35,741 36,193 Hypothetical protein + 150 MAM_066 54 ΦMAM1a YP_007349045.1
40 36,281 36,430 Hypothetical protein + 49 KAK25_00040 69 PA25 YP_006299904.1
41 36,764 36,955 Hypothetical protein + 63 ORF038 94 PA73 YP_001293445.1
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The host bacterium for DLP1 and DLP2, S. maltophilia,
has been isolated from nutrient-limited environments,
such as ultrapure and deionized water [2, 53]. The pres-
ence of MazG in DLP1 and DLP2 could potentially offer
a competitive advantage over MazG-deficient phages
replicating in stationary phase S. maltophilia.
Phage relatedness
The two S. maltophila phages DLP1 and DLP2 differ
from each other based upon RFLP analysis, DNA com-
parison analysis, protein:protein comparison analysis,
the presence of insertions/deletions (indels), genetic syn-
teny, as well as the phenotypic differences presented,
which include different host ranges and the timing of
plaque formation. Based upon these analyses, which in-
clude changes to both structural and replication genes
and their predicted gene products, we conclude that
they are significantly different enough in genetic content
and biology to be considered individual phages and not
merely variants of one another. There is sufficient gen-
omic, proteomic and biological differences that, although
they are related phages, DLP1 and DLP2 are not (or are
no longer) close variants of each other. These differences
include 1369 base pair changes and 157 gaps required to
align the DNA, and three genomic locations where
DLP1 and DLP2 have acquired completely different
genes, which originate from entirely different sources
(Additional file 2: Table S2). In DLP1, ORF 32 encodes a
protein of 175 amino acids with no known homolog,
whereas in DLP2, ORF 32 encodes a 53 amino acid
protein that is homologous to a gene found in phage
PA25. In DLP1, ORF 39 encodes a 66 amino acid protein
without a homolog, whereas DLP2 encodes a protein
150 amino acids in length, also with without known ho-
mologs. In DLP2, ORF 55 encodes a 55 amino acid pro-
tein that has homologs in both PA25 and PA73, whereas
DLP1 has no coding DNA in this region of its genome.
Besides these obvious differences, and even though these
phages exhibit high average identity across their entire
genomes and share almost all proteins, it is still possible
that the differences within protein sequences may be as-
sociated with the functional differences displayed during
bacterial host infection. For example, there are proteins
that differ significantly between DLP1 and DLP2 (i.e. a
large number of gaps are required to complete align-
ment), such as ORFs 13, 21, 33, 48, 51 and 54 (encoding a
hypothetical protein, a tail tape measure structural protein,
a hypothetical protein, a VSR endonuclease replication
protein, a hypothetical protein and a dCMP deaminase
replication protein, respectively).
Similar to bacterial relatedness, we suggest that phage
relatedness is an arbitrary ideal, and that there are no set
guidelines as to what constitutes a phage variant versus
what is a different but related phage. In order of related-
ness, it is clear that DLP1 is most related to DLP2, and
then in order of decreasing relatedness, Pseudomonas
phages PA25, PA73, Ab26 and finally Burkholderia
phage KL1 (Additional file 2: Table S2). Together, they
are similar enough to be considered as a Siphoviridae
sub-family, but how would one delineate them as
Table 4 Bacteriophage DLP2 genome annotation (Continued)
42 36,952 37,248 Hypothetical protein + 98 ORF039 100 PA73 YP_001293446.1
43 37,269 37,424 Hypothetical protein + 59 Hypothetical protein 92 Ab26 YP_009044375.1
44 37,399 37,641 Hypothetical protein + 80 ORF040 99 PA73 YP_001293447.1
45 37,748 37,945 Hypothetical protein + 73 X805_23910 58 DSM 6575b KDB52021.1
46 37,993 38,367 Hypothetical protein + 124 KAK25_00046 97 PA25 YP_006299910.1
47 38,428 38,649 Hypothetical protein + 73 KAK25_00047 99 PA25 YP_006299911.1
48 38,646 39,182 Vsr endonuclease + 178 KAK25_00048 100 PA25 YP_006299912.1
49 39,170 39,385 Hypothetical protein + 71 Hypothetical protein 100 Ab26 YP_009044380.1
50 39,382 39,561 Hypothetical protein + 59 KAK25_00050 98 PA25 YP_006299914.1
51 39,622 39,927 Hypothetical protein + 101 ORF045 100 PA73 YP_001293452.1
52 39,944 40,234 Hypothetical protein + 96 ORF046 99 PA73 YP_001293453.1
53 40,227 40,460 Hypothetical protein + 77 KAK25_00053 99 PA25 YP_006299917.1
54 40,531 40,698 Hypothetical protein + 55 ORF048 100 PA73 YP_001293455.1
55 40,689 41,156 dCMP deaminase + 145 dCMP deaminase 97 PA25 YP_009044383.1
56 41,162 41,545 Hypothetical protein + 127 ORF050 100 PA73 YP_001293457.1
57 41,580 41,789 Hypothetical protein + 69 ORF051 100 PA73 YP_001293458.1
58 41,873 42,445 Hypothetical protein + 190 ORF052 99 PA73 YP_001293459.1
aSerratia phage ΦMAM1
bSphaerotilus natans subsp. natans DSM 6575
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variants of the same phage versus related phages of a
continuum? For example, DLP2 is more related to PA25
circa ORF 32, and more related to PA25 and PA73 circa
ORF 55, than DLP1, even though DLP2 shares the most
homology with DLP1. Therefore, how much genetic,
proteomic and biological differences must be evident be-
fore phages are separated into different “species”? Based
upon the biological differences (including host range
and plaque formation differences), the significant genetic
alterations (including the presence of “indels”), and the
protein level differences (highly variable but related pro-
tein sequences) presented, we conclude that each of
these phages are different but related phages. These ana-
lyses confirm the idea that, although the phage genome
DNA sequences are syntenic, significant changes have
occurred between every member of this sub-family of
phages, which is also reflected in the biological differ-
ences exhibited by phages DLP1 and DLP2.
Conclusions
Although relatively rare, the incidence of phage broad
host range specificity at the genera level is being increas-
ingly studied in the food production industry, mainly with
the Salmonella and Escherichia genera [54–57]. This
study is the first to identify and characterize phages
capable of infecting pathogenic bacteria across taxonomic
orders. DLP1 and DLP2 are closely related phages that
share a high similarity to P. aeruginosa phages vB_Pae-
Kakheti25, vB_PaeS_SCH_Ab26, and PA73 and lesser
similarity to Burkholderia phage KL1. Phage DLP1, pos-
sessing a 42,887 bp genome, is predicted to encode 57
proteins and exhibits a delayed plaque development
phenotype. Unlike DLP1, phage DLP2 exhibits normal
plaque development, but possesses a relatively similar gen-
ome 42,593 bp in length. The cause of the delayed plaque
development in phage DLP1 is yet unknown, but genomic
comparison suggests that gene variants encoded by or
genes acquired by DLP1 may contribute to the observed
lysis phenotype differences. The use of phage therapy may
be one of the best treatment options for otherwise un-
treatable drug resistant bacterial infections [5, 11, 58]. The
genomic characterization of broad-host range phages such
as DLP1 and DLP2 is the first step towards developing an
effective phage therapy strategy for S. maltophilia.
Methods
Bacterial strains and growth conditions
Five S. maltophilia and eight P. aeruginosa strains were
acquired from the Canadian Burkholderia cepacia com-
plex Research and Referral Repository (Vancouver, BC).
The S. maltophilia strains used for isolation of phage
from soil samples were D1585, D1571, D1614, D1576
and D1568. An additional 22 S. maltophilia strains were
gifted from the The Provincial Laboratory for Public
Health - North (Microbiology), Alberta Health Services,
for host range analysis. All strains were grown aerobic-
ally overnight at 30 °C on half-strength Luria-Bertani
(½ LB) solid medium or in ½ LB broth with shaking at
225 RPM.
Phage isolation, propagation and electron microscopy
DLP1 and DLP2 were isolated from Red Deer River
sediment and Linum lewisii (blue flax) soil, respectively,
using standard extraction protocols [59]. Environmental
samples were incubated with shaking at 30 °C in ½ LB
broth, modified suspension medium (SM) (50 mM
Tris–HCl [pH 7.5], 100 mM NaCl, 10 mM MgSO4), and
S. maltophlia D1585 liquid culture. Solids were pelleted
by centrifugation and the supernatant was filter-sterilized
using a Millex-HA 0.45 μm syringe driven filter unit
(Millipore, Billerica, MA). These were plated in soft agar
overlays with strain D1585, and incubated overnight at
30 °C followed by observation for >24 h at room
temperature. For each environmental sample, a single
plaque was isolated using a sterile Pasteur pipette, sus-
pended in 500 μl of modified SM with 20 μl chloroform
and incubated 1 h at room temperature to generate
stocks for DLP1 and DLP2.
Propagation of the phages was performed using soft
agar overlays: 100 μl liquid culture and 100 μl phage stock
were incubated 20 min at room temperature, mixed with
3 ml 0.7 % ½ LB top agar, overlaid on a plate of ½ LB solid
medium, and incubated at 30 °C until plaque formation
was complete. High titre stocks were made by overlaying
plates with confluent lysis with 3 ml modified SM and in-
cubated >1 h at room temperature on a platform rocker.
The supernatant was recovered, pelleted by centrifugation
for 5 min at 10,000 × g, filter-sterilized using a Millex-HA
0.45 μm syringe-driven filter unit (Millipore, Billerica,
MA) and stored at 4 °C. Titre of stocks was obtained using
serial dilutions of phage stock into SM, followed by soft
agar overlay technique and incubation at 30 °C until
plaque formation was complete.
For electron microscopy, phage stocks were prepared
as described above with the following modifications: ½
LB agarose plates and ½ LB soft agarose were used for
overlays, MilliQ-filtered water for phage recovery and
a 0.22 μm filter was used for syringe-driven filtration.
A carbon-coated copper grid was incubated with lysate
for 2 min and stained with 4 % uranyl acetate for 30 s.
Transmission electron micrographs were captured
using a Philips/FEI (Morgagni) transmission electron
microscope with charge-coupled device camera at
80 kV (University of Alberta Department of Biological
Sciences Advanced Microscopy Facility). The capsid
diameter and tail length was calculated using Microsoft
Excel based on measurements from nine individual
virions.
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Phage host range analysis, and PCR confirmation
Host range analysis was performed using a panel of 27
clinical S. maltophilia and 19 P. aeruginosa strains
(Tables 1 and 2), and 25 other Pseudomonas and Gram-
negative bacterial species (Additional file 1: Table S1).
Soft-agar overlays containing 100 μl liquid bacterial cul-
ture were allowed to solidify for 10 min at room
temperature. These plates were spotted with 10 μl drops
of DLP1 or DLP2 at multiple dilutions and assayed for
clearing (confluent phage lysis), and/or plaque formation
after incubation for 36 h at 30 °C. If plaques were
formed, a single plaque from a successful infection plate
was picked to propagate as a working stock solution for
further analysis. In order to confirm that the plaque con-
tained DLP1 or DLP2 particles, PCR analysis was con-
ducted on each purified phage solution using TopTaq
DNA polymerase and buffers (Qiagen) and primers spe-
cific to each phage (DLP1F: ACACTGGCGAAGGAT
TACGG, DLP1R: GCCTTTCGAAATTCGCCGTT and
DLP2F: CGGCTTTTTCGTGCCTGTAA, DLP2R:ACTC
CTTTTCGATGCGTCCG) (Sigma-Genosys, Oakville,
ON). These PCR products correspond to regions of
DNA encoding part of ORF38, ORF39 and ORF40 in
DLP1 and part of ORF38 and ORF39 in DLP2. PCR
products were separated and visualized on a 1 % (wt/vol)
agarose gel in 1x TAE (pH 8.0), and the product authen-
ticity was confirmed by DNA sequencing. This test is a
control experiment designed to ensure that the applica-
tion of an exogenous phage does not induce a resident
prophage into production. All samples that were positive
for the production of phage clearing or plaques were
subjected to confirmation of DLP1 or DLP2 phage pro-
duction by PCR.
Phage DNA isolation, RFLP analysis and sequencing
DLP1 and DLP2 genomic DNA was isolated from bac-
teriophage lysate using the Wizard Lambda DNA purifi-
cation system (Promega Corp., Madison, WI) with a
modified protocol [60, 61]. A 10 ml aliquot of filter-
sterilized phage lysate (propagated on D1585 with agar-
ose medium) was treated with 10 μl DNase I (Thermo
Scientific, Waltham, MA), 100 μl 100x DNase I buffer
(1 M Tris–HCl, 0.25 M MgCl2, 10 mM CaCl2), and 6 μl
RNase (Thermo Scientific) and incubated 1 h at 37 °C to
degrade the bacterial nucleic acids. Following incubation,
400 μl of 0.5 M EDTA and 25 μl of 20 mg/ml proteinase
K (Applied Biosystems, Carlsbad, CA) were added and
incubated 1 h at 55 °C to inactivate DNase I. After cool-
ing to room temperature, the lysate was added to 8.4 g
of guanidine thiocyanate, along with 1 ml of 37 °C resus-
pended Wizard DNA Clean-Up Resin (Promega Corpor-
ation, Madison, WI). This mixture was rocked for
10 min, and then pelleted by centrifugation at room
temperature for 10 min at 5000 x g. The supernatant
was drawn off until ~5 ml remained. This mixture was
resuspended by swirling, transferred into a syringe at-
tached to a Wizard Minicolumn (Promega Corporation),
and pushed through the column. The column was then
washed with 2 ml 80 % isopropanol and dried by centri-
fugation for 2 min at 10,000 x g. Phage DNA was eluted
from the column following a 1 min incubation of 100 μl
of 80 °C nuclease-free water (Integrated DNA Technolo-
gies, Coralville, IA) and centrifugation for 1 min at
10,000 x g. A NanoDrop ND-1000 spectrophotometer
(Thermo Scientific, Waltham, MA) was used to deter-
mine purity and concentration of eluted DNA.
For each phage DNA sample, restriction fragment
length polymorphism analysis was performed using
three - 20 μl FastDigest EcoRI (Thermo Scientific) reac-
tions containing l μg of phage DNA. Reactions were
incubated at 37 °C for 5 min and separated on a 1 %
(wt/vol) agarose gel in 1x TAE (pH 8.0). Preliminary se-
quencing of EcoRI phage DNA fragments cloned into
pUC19 was performed as described previously [62, 63].
Phage DNA was submitted to The Applied Genomics
Core at the University of Alberta for sequencing using
MiSeq (Illumina, San Diego, CA) and assembled using
the CLC Genomics Workbench (Qiagen, Toronto, ON).
The genome sequences of DLP1 and DLP2 have been
deposited in GenBank with the accession numbers
KR537872 and KR537871, respectively.
Bioinformatics analysis
Open reading frames (ORFs) for each contig were identi-
fied using the GLIMMER plugin [64] for Geneious [65]
using the Bacteria and Archaea setting, as well as Gene-
MarkS (http://exon.gatech.edu/GeneMark/genemarks.cgi)
for phage [66]. Conserved domain searches were per-
formed using CD-Search [67]. The contigs were annotated
using BLASTN and BLASTP (for full genomes and indi-
vidual proteins, respectively) [68]. BLASTX and PHAST
were used to search for similar sequences in the Gen-
Bank database. Sequence comparisons were visualized
using Circos (http://circos.ca) [69] and NUCmer (http://
mummer.sourceforge.net) [70] with the following parame-
ters: breaklen = 200, maxgap = 90, mincluster = 65, min-
match = 20. Lysis protein analysis was performed using
TMHMM for transmembrane region identification
(http://www.cbs.dtu.dk/services/TMHMM/) [40].
Availability of supporting data
Supporting data in the form of “Additional file 1: Table
S1.” can be accessed through LabArchives, LLC at doi:
10.6070/H4CJ8BGT . Supporting data in the form of
“Additional file 2: Table S2.” can be accessed through
LabArchives, LLC at doi: 10.6070/H4H9936J .
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Additional files
Additional file 1: Table S1. Bacterial Species and Strains Not Sensitive
to Phages DLP1 or DLP2. Twenty five different Pseudomonasand other
Gram-negative bacteria were tested for sensitivity to phages DLP1 and
DLP2 using high- and low-titre plaque overlay assays. None of the add-
itional species or strains were observed to be infected or form plaques
under the conditions tested. (DOCX 36 kb)
Additional file 2: Table S2. Protein: protein comparison of the
predicted proteins encoded by phages DLP1 (vB_SmaS-DLP_1),
DLP2(vB_SmaS-DLP_2), vB_Pae-Kakheti25, vB_PaeS_SCH_Ab26, PA73, and
KL1 (vB_BceS_KL1). Pairwise comparison was carried out using BLSATP
analysis, and important relationships and descriptivecharacteristics were
determined. (DOCX 70 kb)
Abbreviations
ATP: Adenosine triphosphate; BLAST: Basic local alignment search tool;
bp: Base pair; dCMP: Deoxycytidine monophosphate; DEAD: Asp-glu-ala-asp;
DNA: Deoxyribonucleic acid; EDTA: Ethylenediaminetetraacetic acid;
FDA: United States Food and Drug Administration; g: Gravitational force or
grams; gp: Gene product; h: Hours; kb: Kilobases; kV: Kilovolts; LB: Luria-
Bertani; M: Molar; min: Minutes; ml: Milliliters; mm: Millimeters;
mM: Millimolar; nm: Nanometers; ORF: Open reading frame; PCR: Polymerase
chain reaction; RNA: Ribonucleic acid; RPM: Rounds per minute; s: Seconds;
SM: Suspension media; TAE: Tris base, acetic acid, EDTA; μl: Microliters;
μm: Micrometers; vsr: Very short patch repair.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KHL isolated DLP1 and DLP2. DLP sequenced, annotated and analyzed the
genomes, performed electron microscopy and drafted the manuscript. KHL
assisted with genome assembly and analysis. PS assisted with the production
of Fig. 6. JJD devised the study and assisted with experimental design, data
analysis and the writing of the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
The authors would like to thank Arlene Oatway from the University of
Alberta Department of Biological Sciences Advanced Microscopy Facility for
assistance with electron microscopy, and members of the Dennis lab for
helpful scientific discussions. The authors thank the Canadian Burkholderia
cepacia complex Research and Referral Repository (CBCCRRR, Vancouver, BC)
and The Provincial Laboratory for Public Health - North (Microbiology),
Alberta Health Services, for gifts of bacterial strains. JJD gratefully
acknowledges operating grant funding from the Natural Sciences and
Engineering Research Council of Canada (NSERC).
Author details
1Department of Biological Sciences, 6-065 Centennial Centre for
Interdisciplinary Science, University of Alberta, Edmonton, AB T6G 2E9,
Canada. 2Department of Agricultural, Food and Nutritional Science, University
of Alberta, 1400 College Plaza, Edmonton, AB T6G 2C8, Canada.
Received: 31 March 2015 Accepted: 14 August 2015
References
1. Aarestrup FM, Aidara-Kane A, Sande-Bruinsma N van de, Falzon D,
Grundmann H, et al. Antimicrobial resistance: global report on surveillance.
World Health Organization; WHO Press, 2014:1–256.
2. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic
pathogen. Clin Microbiol Rev. 2012;25:2–41.
3. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic
Stenotrophomonas maltophilia infection and mortality or lung
transplantation in cystic fibrosis patients. J Cyst Fibros. 2013;12:482–6.
4. Wainwright CE, France MW, O’Rourke P, Anuj S, Kidd TJ, Nissen MD, et al.
Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-
negative bacteria from patients with cystic fibrosis. BMJ. 2009;64:926–31.
5. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, et al. Phage
therapy in clinical practice: treatment of human infections. Curr Pharm
Biotechnol. 2010;11:69–86.
6. Semler DD, Lynch KH, Dennis JJ. The promise of bacteriophage therapy for
Burkholderia cepacia complex respiratory infections. Front Cell Infect
Microbiol. 2012;1:27.
7. Hoe S, Semler DD, Goudie AD, Lynch KH, Matinkhoo S, Finlay WH, et al.
Respirable bacteriophages for the treatment of bacterial lung infections. J
Aerosol Med Pulm Drug Deliv. 2013;26:317–35.
8. Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting phage therapy:
new applications for old resources. Trends Microbiol. 2015;23:185–91.
9. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC.
Bacteriophage therapy: potential uses in the control of antibiotic-resistant
pathogens. Expert Rev Anti Infect Ther. 2011;9:775–85.
10. Chanishvili N. Phage therapy–history from Twort and d'Herelle through
Soviet experience to current approaches. Adv Virus Res. 2012;83:3–40.
11. Seed KD, Dennis JJ. Experimental bacteriophage therapy increases
survival of Galleria mellonella larvae infected with clinically relevant
strains of the Burkholderia cepacia complex. Antimicrob Agents
Chemother. 2009;53:2205–8.
12. Hagens S, Habel A, Ahsen U, von Gabain A. Therapy of experimental
Pseudomonas infections with a nonreplicating genetically modified phage.
Antimicrob Agents Chemother. 2004;28:3817.
13. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L.
Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic
fibrosis strains: first steps towards treatment and prevention. PLoS One.
2011;6(2):e16963.
14. Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents
for the treatment of murine burn wound infection caused by Klebsiella
pneumoniae B5055. J Med Microbiol. 2011;60:205–10.
15. Waseh S, Hanifi-Moghaddam P, Coleman R, Masotti M, Ryan S, Foss M, et al.
Orally administered P22 phage tailspike protein reduces Salmonella
colonization in chickens: prospects of a novel therapy against bacterial
infections. PLoS One. 2010;5(11):e13904.
16. Golshahi L, Lynch KH, Dennis JJ, Finlay WH. In vitro lung delivery of
bacteriophages KS4-M and Î¦KZ using dry powder inhalers for treatment of
Burkholderia cepacia complex and Pseudomonas aeruginosa infections in
cystic fibrosis. J Appl Microbiol. 2011;110:106–17.
17. Semler DD, Goudie AD, Finlay WH, Dennis JJ. Aerosol phage therapy
efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob
Agents Chemother. 2014;58:4005–13.
18. Wright A, Hawkins CH, AnggÃ¥rd EE, Harper DR. A controlled clinical trial of
a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-
resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin
Otolaryngol. 2009;34:349–57.
19. Merabishvili M, Pirnay J, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N,
et al. Quality-controlled small-scale production of a well- defined
bacteriophage cocktail for use in human clinical trials. PLoS One.
2009;4:e4944.
20. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze
A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase
I safety trial. J Wound Care. 2009;18:237–8. 240–3.
21. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human
infections. Bacteriophage. 2011;1:66–85.
22. Chang HC, Chen CR, Lin JW, Shen GH, Chang KM, Tseng YH, et al. Isolation
and characterization of novel giant Stenotrophomonas maltophilia phage
phiSMA5. Appl Environ Microbiol. 2005;71(3):1387–93.
23. Hagemann M, Hasse D, Berg G. Detection of a phage genome carrying a
zonula occludens like toxin gene (zot) in clinical isolates of
Stenotrophomonas maltophilia. Arch Microbiol. 2006;185(6):449–58.
24. Chen CR, Lin CH, Lin JW, Chang CI, Tseng YH, Weng SF. Characterization of
a novel T4-type Stenotrophomonas maltophilia virulent phage Smp14. Arch
Microbiol. 2007;188(2):191–7.
25. Fan H, Huang Y, Mi Z, Yin X, Wang L, Fan H, et al. Complete Genome
Sequence of IME13, a Stenotrophomonas maltophilia bacteriophage with
large burst size and unique plaque polymorphism. J Virol.
2012;86(20):11392–3.
26. Huang Y, Fan H, Pei G, Fan H, Zhang Z, An X, et al. Complete
genome sequence of IME15, the first T7-like bacteriophage lytic to
pan-antibiotic-resistant Stenotrophomonas maltophilia. J Virol.
2012;86(24):13839–40.
Peters et al. BMC Genomics  (2015) 16:664 Page 14 of 15
27. Lee CN, Tseng TT, Chang HC, Lin JW, Weng SF. Genomic sequence of
temperate phage Smp131 of Stenotrophomonas maltophilia that has similar
prophages in xanthomonads. BMC Microbiol. 2014;14:17.
28. Liu J, Liu Q, Shen P, Huang YP. Isolation and characterization of a novel
filamentous phage from Stenotrophomonas maltophilia. Arch Virol.
2012;157(9):1643–50.
29. Petrova M, Shcherbatova N, Kurakov A, Mindlin S. Genomic characterization
and integrative properties of phiSMA6 and phiSMA7, two novel filamentous
bacteriophages of Stenotrophomonas maltophilia. Arch Virol.
2014;159(6):1293–303.
30. GarcÃa P, MonjardÃn C, MartÃn R, Madera C, SoberÃ³n N, Garcia E, et al.
Isolation of new Stenotrophomonas bacteriophages and genomic
characterization of temperate phage S1. Appl Environ Microbiol.
2008;74:7552–60.
31. Lacroix-Gueu P, Briandet R, LÃ©vÃªque-Fort S, Bellon-Fontaine MN,
Fontaine-Aupart MP. In situ measurements of viral particles diffusion inside
mucoid biofilms. C R Biol. 2005;328(12):1065–72.
32. Briandet R, Lacroix-Gueu P, Renault M, Lecart S, Meylheuc T, Bidnenko E,
et al. Fluorescence correlation spectroscopy to study diffusion and reaction of
bacteriophages inside biofilms. Appl Environ Microbiol. 2008;74(7):2135–43.
33. Lynch KH, Stothard P, Dennis JJ. Comparative analysis of two
phenotypically-similar but genomically-distinct Burkholderia cenocepacia-
specific bacteriophages. BMC Genomics. 2012;13:223.
34. Sullivan MB, Waterbury JB, Chisholm SW. Cyanophages infecting the
oceanic cyanobacterium Prochlorococcus. Nature. 2003;424:1047–51.
35. Watkins SC, Smith JR, Hayes PK, Watts JEM. Characterisation of host growth
after infection with a broad-range freshwater cyanopodophage. PLoS One.
2014;9:e87339.
36. Weitz JS, Poisot T, Meyer JR, Flores CO, Valverde S, Sullivan MB, et al. Phage-
bacteria infection networks. Trends Microbiol. 2013;21:82–91.
37. Karumidze N, Thomas JA, Kvatadze N, Goderdzishvili M, Hakala KW,
Weintraub ST, et al. Characterization of lytic Pseudomonas aeruginosa
bacteriophages via biological properties and genomic sequences. Appl
Microbiol Biotechnol. 2012;94:1609–17.
38. Kwan T, Liu J, Dubow M, Gros P, Pelletier J. Comparative genomic analysis
of 18 Pseudomonas aeruginosa bacteriophages. J Bacteriol.
2006;188(3):1184–7.
39. Pellegrin V, Juretschko S, Wagner M, Cottenceau G. Morphological and
biochemical properties of a Sphaerotilus sp. isolated from paper mill slimes.
Appl Environ Microbiol. 1999;65:156–62.
40. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting
transmembrane protein topology with a hidden Markov model: application
to complete genomes. J Mol Biol. 2001;305:567–80.
41. Berry J, Summer EJ, Struck DK, Young R. The final step in the phage
infection cycle: the Rz and Rz1 lysis proteins link the inner and outer
membranes. Mol Microbiol. 2008;70:341–51.
42. Berry J, Savva C, Holzenburg A, Young R. The lambda spanin components
Rz and Rz1 undergo tertiary and quaternary rearrangements upon complex
formation. Protein Sci. 2010;19:1967–77.
43. Summer EJ, Berry J, Tran TAT, Niu L, Struck DK, Young R. Rz/Rz1 lysis gene
equivalents in phages of Gram-negative hosts. J Mol Biol. 2007;373:1098–112.
44. Juncker AS, Willenbrock H, Von Heijne G, Brunak S, Nielsen H, Krogh A.
Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein
Sci. 2003;12:1652–62.
45. Söding J, Biegert A, Lupas AN. The HHpred interactive server for protein
homology detection and structure prediction. Nucleic Acids Res.
2005;33(Web Server issue):W244–8.
46. Owttrim GW. RNA helicases: diverse roles in prokaryotic response to abiotic
stress. RNA Biol. 2013;10:96–110.
47. Mechold U, Potrykus K, Murphy H, Murakami KS, Cashel M. Differential
regulation by ppGpp versus pppGpp in Escherichia coli. Nucleic Acids Res.
2013;41:6175–89.
48. Magnusson LU, Farewell A, Nyström T. ppGpp: A global regulator in
Escherichia coli. Trends Microbiol. 2005;13(5):236–42.
49. Maciag M, Kochanowska M, Lyzeń R, Wegrzyn G, Szalewska-Pałasz A. ppGpp
inhibits the activity of Escherichia coli DnaG primase. Plasmid. 2010;63:61–7.
50. Gross M, Marianovsky I, Glaser G. MazG – a regulator of programmed cell
death in Escherichia coli. Mol Microbiol. 2006;59:590–601.
51. Bryan MJ, Burroughs NJ, Spence EM, Clokie MRJ, Mann NH, Bryan SJ.
Evidence for the intense exchange of MazG in marine cyanophages by
horizontal gene transfer. PLoS One. 2008;3:e2048.
52. Clokie MRJ, Mann NH. Marine cyanophages and light. Environ Microbiol.
2006;8:2074–82.
53. Arvanitidou M, Vayona A, Spanakis N, Tsakris A. Occurrence and
antimicrobial resistance of Gram-negative bacteria isolated in haemodialysis
water and dialysate of renal units: results of a Greek multicentre study. J
Appl Microbiol. 2003;95:180–5.
54. Matilla MA, Salmond GPC. Bacteriophage ΦMAM1, a viunalikevirus, is a
broad-host-range, high-efficiency generalized transducer that infects
environmental and clinical isolates of the enterobacterial genera Serratia
and Kluyvera. Appl Environ Microbiol. 2014;80:6446–57.
55. Bielke L, Higgins S, Donoghue A, Donoghue D, Hargis BM. Salmonella host
range of bacteriophages that infect multiple genera. Poult Sci.
2007;86:2536–40.
56. Park M, Lee J-H, Shin H, Kim M, Choi J, Kang D-H, et al. Characterization and
comparative genomic analysis of a novel bacteriophage, SFP10,
simultaneously inhibiting both Salmonella enterica and Escherichia coli
O157:H7. Appl Environ Microbiol. 2012;78:58–69.
57. Kim M, Ryu S. Characterization of a T5-like coliphage, SPC35, and differential
development of resistance to SPC35 in Salmonella enterica serovar
typhimurium and Escherichia coli. Appl Environ Microbiol. 2011;77:2042–50.
58. Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF. Synergistic phage-
antibiotic combinations for the control of Escherichia coli biofilms in vitro.
Immunol Med Microbiol. 2012;65:395–8.
59. Seed KD, Dennis JJ. Isolation and characterization of bacteriophages of the
Burkholderia cepacia complex. FEMS Microbiol Lett. 2005;251:273–80.
60. DNA isolation from Lambda lysates using the Wizard® DNA Clean-Up
System. [http://www.promega.ca/resources/pubhub/enotes/dna-isolation-
from-lambda-lysates-using-the-wizard-dna-cleanup-system/].
61. Lynch KH, Abdu AH, Schobert M, Dennis JJ. Genomic characterization of
JG068, a novel virulent podovirus active against Burkholderia cenocepacia.
BMC Genomics. 2013;14:574.
62. Lynch KH, Seed KD, Stothard P, Dennis JJ. Inactivation of Burkholderia
cepacia complex phage KS9 gp41 identifies the phage repressor and
generates lytic virions. J Virol. 2010;84:1276–88.
63. Lynch KH, Stothard P, Dennis JJ. Genomic analysis and relatedness of P2-like
phages of the Burkholderia cepacia complex. BMC Genomics. 2010;11:599.
64. Delcher AL, Bratke KA, Powers EC, Salzberg SL. Identifying bacterial genes
and endosymbiont DNA with Glimmer. Bioinformatics. 2007;23:673–9.
65. Drummond A, Ashton B, Buxton S, Cheung M, Cooper A, Duran C, et al.
Geneious. 2013.
66. Besemer J, Lomsadze A, Borodovsky M. GeneMarkS: a self-training method
for prediction of gene starts in microbial genomes. Implications for finding
sequence motifs in regulatory regions. Nucleic Acids Res. 2001;29:2607–18.
67. Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-
Scott C, et al. CDD: a conserved domain database for the functional
annotation of proteins. Nucleic Acids Res. 2011;39(Database issue):D225–9.
68. Altschul S, Madden T. Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs. Nucleic Acids. 1997;25:3389–402.
69. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al.
Circos: An information aesthetic for comparative genomics. Genome Res.
2009;19:1639–45.
70. Delcher AL, Phillippy A, Carlton J, Salzberg SL. Fast algorithms for large-scale
genome alignment and comparison. Nucleic Acids Res. 2002;30:2478–83.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Peters et al. BMC Genomics  (2015) 16:664 Page 15 of 15
